LACERTA

LACERTA
BOT100

BOT100

FDA APPROVED. CLINICALLY PROVEN.

Wrinkles, or 11ths, appear when facial expressions of the least severity appear under the skin. Meanwhile, as the skin ages, recurring wrinkles become permanent. BOT100®, available on prescription, blocks the release of key substances that cause muscle contractions, resulting in smoother wrinkles.

MODERN PRODUCTION PROCESS.

The clean beauty trend is here. BOT100® is a new generation of proteins manufactured using a unique precision manufacturing process called MAKRO Japan Technology™, which uses ten stages of filtration to isolate the therapeutic component of the molecule and remove complexing/unnecessary proteins that do not play an active role in treatment. BOT100® is a protein with ten levels of filtration. Direct studies assessing the relative risk of immunogenicity due to the presence or absence of complexing/junk proteins have not been performed.

Process protein formula

We believe that product purity and potency matter. That’s why we take the time to filter our protein process in ten stages using our patented MAKRO Japan Technology™ process.

Step by step

Our unique formula removes unnecessary proteins so the active ingredient contains only what is needed to smooth wrinkles, treatment after treatment.* Time is on your side, and so are we.

*Effect may vary depending on individual physical characteristics of the patient, injection method and type procedures.

Storage instruction
Keep sealed and store at 2~8°C
Expiry date
36 months from date of manufacture
Packing unit
1 vial
Division
POM (prescription-only medicine)
Appearance
A white injectable dry powder in a transparent glass vial which should become a colorless, transparent liquid when reconstituted with a solvent (normal saline solution)
Efficacy / effect
1. The Treatment of Positive Essential Eyelid Convulsion in Adults aged 18 and over
2. Temporary Improvement of Severe Lasso wrinkles in Adults aged 18 to 65 years of age, associated with Corrugator Muscle and/or Procerus Muscle activities
3. Muscle Stroke : Treatment of Upper Limb Stroke in Adults aged 20 or older
4. Treatment of Dynamic Equinus Foot Deformity in children with cerebral palsy over 2 years old. Temporary Improvement of External Angles (Eye Wrinkles) of Secondary Ideals Related to Orbicularis Oculi Muscle Activity in Adults aged 19 to 65
  • Known hypersensitivity to the active substance botulinum neurotoxin type A or to any of the excipients.
  • Infection at intended injection sites.
  • Difficulty breathing, speaking, or swallowing: Increased risk if bilateral neck muscle injections are required or with pre-existing muscle conditions; Immediate medical attention may be required.
  • The active ingredients of BOT100 are not interchangeable with other drugs containing protein.
  • Corneal exposure and ulceration: Protective measures may be required.
  • Risk of developing ptosis: Follow dosage recommendations.

dibasic polypeptide

*LACERTA BOT100 can be affected by improper storage conditions like heat, humidity, etc. resulting in a change of colour.
Please note that on occasion product package design can change, we will always strive to show the present design where possible
**The majority of our products are designed for professional use by doctors and specialists, by purchasing said product(s) you agree to supply on request formal proof of medical/professional training. Said product(s) are not intended for personal or home use.
Please note this product has contraindications for use. It is recommended that all Healthcare professionals familiarise themselves with these contraindications and precautions by reading the instructions provided.

Lacerta Tokyo Сo.,Ltd.

Privacy policy

Refusal of unauthorized collection of email

Copyright © 2016 LACERTA, Inc. All rights reserved.